Gossamer Bio, Inc. (Nasdaq: GOSS), a forward-thinking biopharmaceutical company, is gearing up to discuss the latest advancements in the development of seralutinib for treating pulmonary arterial hypertension (PAH). The company has announced a public conference call and webcast scheduled for Monday, December 18, 2023, at 8:30 am ET.
Seralutinib, a cutting-edge tyrosine kinase inhibitor, targets PDGFRα/β, CSF1R, and c-KIT. It is uniquely designed for delivery via a dry powder inhaler, offering a promising solution for pulmonary hypertension treatment.
The conference call aims to shed light on the ongoing TORREY Phase 2 Open-Label Extension Study and present the latest clinical data on seralutinib in PAH patients. Investors and analysts eager for insights into these developments are invited to join the discussion.
Event Details:
- Date / Time: December 18, 8:30 am EST
- Dial-in Number: 1-800-285-6670
- Conference Reference: Gossamer Bio – Torrey OLE Update
- Live Webcast: Link to Webcast
For those unable to attend live, a replay of the audio webcast will be available on the “Investors” section of Gossamer Bio’s website, www.gossamerbio.com, for 30 days following the event.
Gossamer Bio is committed to pioneering advancements in the treatment of pulmonary arterial hypertension, with a primary focus on seralutinib. The company aspires to lead the industry and improve the lives of patients grappling with pulmonary hypertension.
For further information, interested parties can visit the official source version on businesswire.com: Gossamer Bio Source
Contact Information: For Investors and Media: Bryan Giraudo, Chief Operating Officer and Chief Financial Officer Gossamer Bio Investor Relations Email: ir@gossamerbio.com Source: Gossamer Bio, Inc.
